Our goal is to enhance, optimize the patients journey with chronic inflammatory diseases, many of which are poorly managed by existing treatments that provide only symptom relief. We seek to address the root cause of this inflammation at a molecular level.
 

Inflammation is a critical response to potential danger signals and damage in organs in our body. But with autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, psoriasis, ulcerative colitis, Crohn’s disease and many others, our own immune system turns against our organs. These painful and debilitating conditions take an immense toll on people’s quality of life and many of these diseases are poorly managed by existing treatments that provide only symptomatic relief.

For decades, doctors relied on steroids to suppress immune response. Though an important option, steroids come with many potentially harmful side effects. Fortunately, science has continued to advance, and today we have the opportunity to transform the management of inflammatory diseases with new classes of therapies that target other key proteins and pathways in the body.
 

As science evolves beyond broad immunosuppression and into more selective agents, patients living with autoimmune and inflammatory disease have new hope. Pfizer scientists operate with a sense of urgency, focused on three areas with the greatest unmet need: Rheumatology, Gastroenterology and Medical Dermatology.